Market Closed -
Nasdaq
04:00:00 2024-05-10 pm EDT
5-day change
1st Jan Change
9.26
USD
-5.41%
-14.65%
+54.85%
Sera Prognostics Appoints Jane Barlow to Nominating and Governance Committee
June 29, 2022 at 05:16 pm EDT
The Board of Sera Prognostics, Inc. appointed Dr. Jane Barlow, M.D., to the nominating and governance committee of the Board, effective immediately.
Transcript : Sera Prognostics, Inc., Q1 2024 Earnings Call, May 08, 2024
May. 08
Sera Prognostics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
May. 08
CI
Sera Prognostics Insider Sold Shares Worth $727,853, According to a Recent SEC Filing
Mar. 28
MT
Sera Prognostics Insider Sold Shares Worth $364,484, According to a Recent SEC Filing
Mar. 27
MT
Transcript : Sera Prognostics, Inc., 2023 Earnings Call, Mar 20, 2024
Mar. 20
Earnings Flash (SERA) SERA PROGNOSTICS Posts Q4 Revenue $41,000
Mar. 20
MT
Sera Prognostics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Mar. 20
CI
Sera Prognostics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Mar. 20
CI
Sector Update: Health Care Stocks Mixed Late Afternoon
Dec. 06
MT
Top Midday Gainers
Dec. 06
MT
Sector Update: Health Care Stocks Rise in Afternoon Trading
Dec. 06
MT
Sector Update: Health Care
Dec. 06
MT
Sera Prognostics Says Study of Preterm Birth Prevention Strategy Met Primary Endpoint Criteria; Shares Surge
Dec. 06
MT
Sera Prognostics Inc. Announces Preliminary Efficacy Met in Pivotal Prime Study Interim Look - Enrollment to Stop Due to Success
Dec. 06
CI
Transcript : Sera Prognostics, Inc., Q3 2023 Earnings Call, Nov 08, 2023
Nov. 08
Earnings Flash (SERA) SERA PROGNOSTICS Posts Q3 Revenue $42,000
Nov. 08
MT
Sera Prognostics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Nov. 08
CI
Citigroup Adjusts Price Target on Sera Prognostics to $2.75 From $3.75, Maintains Neutral Rating
23-08-10
MT
Transcript : Sera Prognostics, Inc., Q2 2023 Earnings Call, Aug 09, 2023
23-08-09
Earnings Flash (SERA) SERA PROGNOSTICS Reports Q2 Revenue $123,000
23-08-09
MT
Sera Prognostics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-08-09
CI
Sera Prognostics, Inc. Announces the Resignation of Michael R. Foley, M.D., as Chief Medical Officer
23-07-31
CI
Sera Prognostics, Inc.(NasdaqGM:SERA) dropped from Russell Microcap Value Index
23-06-23
CI
Sera Prognostics, Inc.(NasdaqGM:SERA) added to Russell Microcap Growth Index
23-06-23
CI
Sera Prognostics, Inc.(NasdaqGM:SERA) added to Russell 3000E Growth Index
23-06-23
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Sera Prognostics, Inc. is a women's health diagnostic company utilizing its proprietary proteomics and bioinformatics platform, and significant data resources to enhance maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. It has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. Its commercial product, the PreTRM test, is a validated, commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation that provides a prediction of the expectant motherâs risk of delivering spontaneously before 37 weeksâ gestation.
More about the company
1st Jan change
Capi.
+54.85% 320M +13.37% 17.19B 0.00% 7.31B -11.55% 2.96B -10.79% 2.79B -29.59% 1.81B -0.07% 1.24B -6.77% 1.08B -10.71% 845M -13.46% 813M
Testing Laboratories
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
SERA PROGNOSTICS, INC. 
